Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jan 16;4(2):129-131.
doi: 10.1016/j.jdcr.2017.09.007. eCollection 2018 Mar.

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Raphael Reinhard  1   2 , Christoffer Gebhardt  1   2 , Nolwenn Maurier  1 , Lionel Larribère  1   2 , Azadeh Orouji  1 , Jochen Utikal  1   2
Affiliations
Case Reports

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Raphael Reinhard et al. JAAD Case Rep. .
No abstract available

Keywords: BRAF; MEK; melanoma; metastases; targeted therapy.

PubMed Disclaimer

Figures

Fig 1
Fig 1
A, Multiple verrucous epidermotropic melanoma metastases on the left leg/lower abdomen before therapy and B, 2 months after CO2 laser therapy and topical imiquimod therapy.
Fig 2
Fig 2
Histology of epidermotropic melanoma metastases. (A, Hematoxylin-eosin stain; B, anti-S100B stain.)
See this image and copyright information in PMC

References

    1. Ascierto P.A., McArthur G.A., Dréno B. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. - PubMed
    1. Long G.V., Stroyakovskiy D., Gogas H. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. - PubMed
    1. Long G.V., Stroyakovskiy D., Gogas H. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. - PubMed
    1. Stadler S., Weina K., Gebhardt C., Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci. 2015;60(1):83–88. - PubMed
    1. Roesch A., Paschen A., Landsberg J., Helfrich I., Becker J.C., Schadendorf D. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. Eur J Cancer. 2016;59:109–112. - PubMed

Publication types

LinkOut - more resources